Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


26.06.2017

1 BMC Neurol
1 Exp Neurol
2 J Neural Transm (Vienna)
1 J Neurochem
1 J Neuropsychol
2 Lancet Neurol
7 Mov Disord
2 Nat Rev Neurol
1 Nature
1 Neurochem Res
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Neurol

  1. KIM Y, Kim A, Kim A, Jeon B, et al
    A case report of thoracolumbar paraspinal myopathy as the cause of camptocormia in a patient with atypical parkinsonism.
    BMC Neurol. 2017;17:118.
    PubMed     Text format     Abstract available


    Exp Neurol

  2. CROTTY GF, Ascherio A, Schwarzschild MA
    Targeting urate to reduce oxidative stress in Parkinson disease.
    Exp Neurol. 2017 Jun 13. pii: S0014-4886(17)30157.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  3. KUBLER D, Schroll H, Buchert R, Kuhn AA, et al
    Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients.
    J Neural Transm (Vienna). 2017 Jun 22. doi: 10.1007/s00702-017-1747.
    PubMed     Text format     Abstract available

  4. BECK G, Singh A, Papa SM
    Dysregulation of striatal projection neurons in Parkinson's disease.
    J Neural Transm (Vienna). 2017 Jun 15. doi: 10.1007/s00702-017-1744.
    PubMed     Text format     Abstract available


    J Neurochem

  5. HAVELUND JF, Andersen AD, Binzer M, Blaabjerg M, et al
    Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
    J Neurochem. 2017 Jun 19. doi: 10.1111/jnc.14104.
    PubMed     Text format     Abstract available


    J Neuropsychol

  6. MARTYR A, Boycheva E, Kudlicka A
    Assessing inhibitory control in early-stage Alzheimer's and Parkinson's disease using the Hayling Sentence Completion Test.
    J Neuropsychol. 2017 Jun 20. doi: 10.1111/jnp.12129.
    PubMed     Text format     Abstract available


    Lancet Neurol

  7. LIU G, Locascio JJ, Corvol JC, Boot B, et al
    Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.
    Lancet Neurol. 2017 Jun 16. pii: S1474-4422(17)30122.
    PubMed     Text format     Abstract available

  8. AARSLAND D, Creese B, Chaudhuri KR
    A new tool to identify patients with Parkinson's disease at increased risk of dementia.
    Lancet Neurol. 2017 Jun 16. pii: S1474-4422(17)30170.
    PubMed     Text format    


    Mov Disord

  9. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Text format     Abstract available

  10. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed     Text format    

  11. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed     Text format    

  12. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Text format     Abstract available

  13. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Text format     Abstract available

  14. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Text format     Abstract available

  15. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed     Text format    


    Nat Rev Neurol

  16. WOOD H
    Parkinson disease: Plasma alpha-synuclein - a potential marker of cognitive impairment in Parkinson disease.
    Nat Rev Neurol. 2017 Jun 23. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    

  17. RIDLER C
    Parkinson disease: Deep brain stimulation - making the right connections.
    Nat Rev Neurol. 2017 Jun 23. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    


    Nature

  18. SULZER D, Alcalay RN, Garretti F, Cote L, et al
    T cells from patients with Parkinson's disease recognize alpha-synuclein peptides.
    Nature. 2017 Jun 21. doi: 10.1038/nature22815.
    PubMed     Text format     Abstract available


    Neurochem Res

  19. NIU J, Xiong J, Hu D, Zeng F, et al
    2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.
    Neurochem Res. 2017 Jun 19. doi: 10.1007/s11064-017-2330.
    PubMed     Text format     Abstract available


    PLoS One

  20. WANG L, Wang Z, Zhu R, Bi J, et al
    Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.
    PLoS One. 2017;12:e0179476.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: